Biotech News

Krystal Biotech to Present at BofA Securities 2026 Health Care Conference

Krystal Biotech (KRYS)Krystal BiotechConference / presentation

Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the BofA Securities 2026 Health Care Conference on May 13, 2026, in Las Vegas. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 11:20 am PT and host investor meetings throughout the day.

A webcast of the presentation will be available here beginning at 11:20 am PT on Wednesday, May 13, 2026 and will be posted on the Investors section of the Company’s website .

About Krystal Biotech, Inc. Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK®, the Company’s first commercial product, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. Visit www.krystalbio.com to learn more or follow us on LinkedIn and X .

CONTACT Investors and Media: Stéphane Paquette, PhD Krystal Biotech spaquette@krystalbio.com

Related news

SANASana Biotechnology2026-05-27 20:05 EST

Sana Biotechnology to Present at June 2026 Investor Conferences

SRPTSarepta Therapeutics2026-05-13 20:30 EST

Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

BCRXBioCryst Pharmaceuticals2026-05-13 11:00 EST

BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026

VYGRVoyager Therapeutics2026-06-11 20:01 EST

Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference

KRYSKrystal Biotech2026-08-03 11:00 EST

Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results

KRYSKrystal Biotech2026-07-23 21:00 EST

Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026

BIIBBiogen2026-07-12 15:18 EST

LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026

SANASana Biotechnology2026-07-01 13:00 EST

Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026

VYGRVoyager Therapeutics2026-06-29 12:01 EST

Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026

CRBUCaribou2026-06-29 12:00 EST

Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

Krystal Biotech

HSV-1 Gene Therapy Platform Krystal Biotech develops genetic medicines using modified, non-replicating herpes simplex virus type 1 vectors. The platform supports repeat local administration and is being applied to diseases affecting skin, eye and lung tissue. VYJUVEK Franchise VYJUVEK is a topical gene therapy approved for wounds in...

Recent company news

Stock data

Close
322.69 USD
Market cap
8.64B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States